NCT02835664CompletedNot Applicable
Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans
Maastricht University Medical Center1 site in 1 country15 target enrollmentStarted: December 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Insulin sensitivity: muscle- and liver specific
Study Overview
Brief Summary
This study will investigate the effects of 6 week Nicotinamide Riboside supplementation (1000 mg/day) on metabolic health in healthy (pre)obese humans. The primary objective will be hepatic and whole body insulin sensitivity. Secondary objectives, to provide information about the underlying mechanism, will be muscle mitochondrial function, brown fat activity, ectopic lipid accumulation, energy metabolism, cardiovascular risk parameters, body composition and acetylcarnitine levels.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 45 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Signed informed consent
- •Caucasian
- •Males and postmenopausal females
- •Aged 45-65 years at start of the study
- •Body mass index (BMI) 27 - 35 kg/m2
- •Stable dietary habits (no weight loss or gain >5kg in the past 3 months)
- •Sedentary lifestyle (not more than 2 hours of sports per week)
Exclusion Criteria
- •Type 2 diabetes
- •Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other)
- •Contra-indication for MRI
- •Participation in earlier research or medical examination that included PET/CT scanning
- •Alcohol consumption of >2 servings per day
- •Smoking in the past 6 months
Outcomes
Primary Outcomes
Insulin sensitivity: muscle- and liver specific
Time Frame: 6 weeks after supplementation
Hyperinsulinemic euglycemic clamp: Rate of glucose disappearance (Rd) will be calculated by using tracer kinetics.
Secondary Outcomes
- Body composition(6 weeks after supplementation)
- Muscle mitochondrial function (ex vivo)(6 weeks after supplementation)
- Ectopic lipid accumulation(6 weeks after supplementation)
- Brown adipose tissue activity(6 weeks after supplementation)
- Cardiovascular risk parameters(6 weeks after supplementation)
- Whole body energy expenditure(6 weeks after supplementation)
- Acetylcarnitine levels(6 weeks after supplementation)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Effects of Nicotinamide Riboside on Metabolism and Vascular FunctionAgingLipemiaNCT03501433Iowa State University16
Completed
Not Applicable
Effects of nicotinamide riboside on metabolic health in obese humansObesityNL-OMON47018Medisch Universitair Ziekenhuis Maastricht15
Withdrawn
Phase 2
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the ElderlyCOVIDNCT04407390University of Copenhagen
Enrolling By Invitation
Not Applicable
NRM on Vascular Perfusion in Healthy AdultsVascular StiffnessNCT06345443Mayo Clinic200
Active, not recruiting
Phase 2
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial MyopathyMitochondrial MyopathyNCT05590468Ralitza Gavrilova34